Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from MAIA Biotechnology, Inc. ( (MAIA) ).
MAIA Biotechnology, Inc. presented a poster at the European Lung Cancer Congress 2025 on March 28, 2025, showcasing efficacy data from its Phase 2 THIO-101 clinical trial. The trial evaluates THIO in combination with the immune checkpoint inhibitor cemiplimab for patients with advanced non-small cell lung cancer who have not responded to standard therapies. This presentation highlights the company’s ongoing efforts to advance its clinical research and potentially improve treatment options for lung cancer patients.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. operates in the biotechnology industry, focusing on developing innovative cancer treatments. The company is engaged in clinical trials to evaluate the efficacy of its product candidates, particularly in the field of oncology.
YTD Price Performance: -22.01%
Average Trading Volume: 283,276
Technical Sentiment Signal: Buy
Current Market Cap: $48.23M
Find detailed analytics on MAIA stock on TipRanks’ Stock Analysis page.